- Home
- IMA vs ACET Comparison
IMA vs ACET Comparison
Compare IMA & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMA | ACET |
|---|---|---|
| Founded | 2019 | 1947 |
| Country | United States | United States |
| Employees | N/A | 152 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.4M | 69.6M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | IMA | ACET |
|---|---|---|
| Price | $6.85 | $7.18 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $16.00 | ★ $65.33 |
| AVG Volume (30 Days) | 45.4K | ★ 182.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.70 | $0.45 |
| 52 Week High | $17.50 | $9.05 |
Technical Indicators
Market Signals| Indicator | IMA | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 49.83 | 51.72 |
| Support Level | $6.65 | $0.62 |
| Resistance Level | $7.17 | $8.74 |
| Average True Range (ATR) | 0.39 | 0.63 |
| MACD | -0.02 | -0.08 |
| Stochastic Oscillator | 32.25 | 39.38 |
Price Performance
Historical ComparisonAbout IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.